Clinical Trials · NCT06874751
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 45,456
- Start date
- Dec 2024
- Locations
- 1 site, United States
- Primary endpoint
- Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event)